COP-AF trial results showed no significant reduction in co-primary endpoints of clinically important AF or myocardial injury after noncardiac thoracic surgery, although there were positive trends.
Aspirin is typically given after PCI for acute coronary syndrome but can lead to major bleeding. Colchicine appears to be safer and may be equally efficacious, pilot data suggest.
Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.